Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-23T21:01:34.608Z Has data issue: false hasContentIssue false
  • English
  • Français

ERK5: A Novel IKKα-Kinase in Rat Hippocampal Neurons

Published online by Cambridge University Press:  02 December 2014

Marc L. Goalstone
Marc L. Goalstone*
Affiliation:
Department of Medicine, University of Colorado Denver and the Research Section of Eastern Colorado Healthcare Service, Denver, Colorado, USA
*
VAMC, Research 151, 1055 Clermont Street, Denver, Colorado, 80220, USA
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

Alzheimer's Disease (AD) is characterized in part by the increased presence of neurofibrillary tangles and amyloid beta (Aβ) plaques. Alzheimer's Disease is considered an inflammatory disease and, as such, nuclear factor-kappaB (NFκB) plays an important role in the pathophysiology of AD. Insulin acts as a neurotrophic factor. Yet, in the context of insulin resistance, concomitant hyperinsulinemia may contribute to the pathogenesis of AD.

Methods:

Rat Primmary Hippocampal Neurons (RPHN) were treated with insulin in the absence and presence of Wortmannin and ERK5 small inhibitory RNA and assayed for downstream effectors of activated ERK5.

Results:

Here we demonstrate that genetic inhibition of ERK5 blocks insulin stimulated (1) activation and translocation of ERK5 and NFκB, (2) phosphorylation of IKKα via association with ERK5, (3) increases in Aβ1-40 and Aβ1-42 soluble proteins 3-fold and 2.2-fold, respectively, and (4) increases in tau phosphorylation in RPHN.

Conclusions:

ERK5 plays an active role in insulin signaling in neurons and may be a potential therapeutic target for neurodegenerative diseases.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 38 , Issue 4 , July 2011 , pp. 639 - 648
Copyright
Copyright © The Canadian Journal of Neurological 2011

References

1.Roberson, ED, Mucke, L.100 years and counting: prospects for defeating Alzheimer’s disease. Science. 2006;314:781–4.Google Scholar
2.Busche, MA, Eichhoff, G, Adelsberger, H, et al.Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer’s disease. Science. 2008;321:1686–9.CrossRefGoogle Scholar
3.Rankin, CA, Sun, Q, Gamblin, TC.Tau phosphorylation by GSK-3beta promotes tangle-like filament morphology. Mol Neurodegener. 2007;2:12–3.CrossRefGoogle ScholarPubMed
4.den Heijer, T, Vermeer, SE, van Dijk, EJ, et al.Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia. 2003;46:1604–10.Google Scholar
5.Granic, I, Dolga, AM, Nijholt, IM, van Dijk, G, Eisel, UL.Inflammation and NF-kappaB in Alzheimer’s disease and diabetes. J Alzheimers Dis. 2009;16:809–21.CrossRefGoogle Scholar
6.Chen, Y-DI and Reaven, GM.Insulin resistance and atherosclerosis. Diabetes Rev. 1997;4:331–42.Google Scholar
7.Cusi, K, Maezono, K, Osman, A, et al.Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest. 2000;105:311–20.CrossRefGoogle ScholarPubMed
8.Ng, SS, Tsao, MS, Nicklee, T, Hedley, DW.Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res. 2001;7:3269–75.Google ScholarPubMed
9.Leitner, JW, Kline, T, Carel, K, Goalstone, M, Draznin, B.Hyperinsulinemia potentiates activation of p21Ras by growth factors. Endocrinology. 1997;138:2211–4.CrossRefGoogle ScholarPubMed
10.Goalstone, ML, Natarajan, R, Standley, PR, et al.Insulin potentiates platelet-derived growth factor action in vascular smooth muscle cells. Endocrinology. 1998;139:4067–72.CrossRefGoogle ScholarPubMed
11.Goalstone, ML, Leitner, JW, Draznin, B.Mechanism of insulin’s ability to potentiate mitogenic effects of growth factors. In: LeRoiths, D, editor. Advances in Molecular and Cellular Endocrinology. 1999. p. 155–73.Google Scholar
12.Chappell, J, Golovchenko, I, Wall, K, et al.Potentiation of Rho-A-mediated lysophophatidic acid activity by hyperinsulinemia. J Biol Chem. 2000;275:31792–7.CrossRefGoogle Scholar
13.Biessels, GJKappelle, LJ.Increased risk of Alzheimer’s disease in Type II diabetes: insulin resistance of the brain or insulininduced amyloid pathology? Biochem Soc Trans. 2005;33: 1041–4.CrossRefGoogle ScholarPubMed
14.Arvanitakis, Z, Wilson, RS, Bienias, JL, Evans, DA, Bennett, DA.Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol. 2004;61:661–6.Google Scholar
15.de la Monte, SM, Wands, JR.Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer’s disease. J Alzheimers Dis. 2005;7:45–61.CrossRefGoogle ScholarPubMed
16.Reagan, LP.Neuronal insulin signal transduction mechanisms in diabetes phenotypes. Neurobiol Aging. 2005;26 Suppl 1:56–9.CrossRefGoogle ScholarPubMed
17.Aljada, A, Saadeh, R, Assian, E, Ghanim, H, Dandona, P.Insulin inhibits the expression of intercellular adhesion molecule-1 by human aortic endothelial cells through stimulation of nitric oxide. J Clin Endo Metab. 2000;85:2572–5.Google ScholarPubMed
18.Golovchenko, I, Goalstone, ML, Watson, P, Brownlee, M, Draznin, B.Hyperinsulinemia enhances transcriptional activity of NFκB induced by angiotensin II, hyperglycemia and advanced glycosylation end products in vascular smooth muscle cells. Circ Res. 2000;87:746–52.CrossRefGoogle ScholarPubMed
19.Mercurio, T, Manning, AM.Multiple signals converging on NFB. Curr Opin Cell Biol. 1999;11:226–32.CrossRefGoogle Scholar
20.Pearson, G, English, JM, White, MA, Cobb, MH.ERK5 and ERK2 cooperate to regulate NF-kappaB and cell transformation. J Biol Chem. 2001;276:7927–31.CrossRefGoogle ScholarPubMed
21.Cude, K, Wang, Y, Choi, HJ, et al.Regulation of the G2-M cell cycle progression by the ERK5-NFkappaB signaling pathway. J Cell Biol. 2007;177:253–64.CrossRefGoogle ScholarPubMed
22.Sharma, G, Goalstone, ML.Regulation of ERK5 by insulin and angiotensin-II in vascular smooth muscle cells. Biochem Biophys Res Commun. 2007;354:1078–83.Google Scholar
23.Paris, D, Patel, N, Quadros, A, et al.Inhibition of Abeta production by NF-kappaB inhibitors. Neurosci Lett. 2007;415:11–6.CrossRefGoogle ScholarPubMed
24.Hotamisligil, GS, Budavari, A, Murray, D, Spiegelman, BM.Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest. 1994;94:1543–9.Google ScholarPubMed
25.Lu, H, Raptis, M, Black, E, Stan, M, Amar, S, Graves, DT.Influence of diabetes on the exacerbation of an inflammatory response in cardiovascular tissue. Endocrinology. 2004;145:4934–9.CrossRefGoogle ScholarPubMed
26.Baeuerle, PA, Baltimore, D.NF-kappa B: ten years after. Cell. 1996; 87:13–20.Google Scholar
27.Baldwin, AS.The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immun 1996;14:49–83.Google ScholarPubMed
28.Ghosh, S, May, MJ, Kopp, EB.NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998;16:225–60.CrossRefGoogle ScholarPubMed
29.Baeuerle, PA, Baichwal, VP.NFκB as a frequent target for immunosuppressive and anti-inflamatory molecules. Adv Immunol. 1997;65:111–37.Google Scholar
30.Ghoda, L, Lin, X, Greene, WC.The 90-kDa ribosomal S6 kinase (pp90rsk) phosphorylates the N-terminal regulatory domain of IkappaBalpha and stimulates its degradation in vitro. J Biol Chem. 1997;272:21281–8.CrossRefGoogle ScholarPubMed
31.Chen, ZJ, Parent, L, Maniatis, T.Site-specific phosphorylation of IkappaBalpha by a novel ubiquitination-dependent protein kinase activity. Cell. 1996;84:853–62.CrossRefGoogle ScholarPubMed
32.Hacker, H, Karin, M.Regulation and function of IKK and IKK-related kinases. Sci STKE. 2006;2006:re13.Google Scholar
33.Hacker, H, Redecke, V, Blagoev, B, et al.Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature. 2006;439:204–7.CrossRefGoogle ScholarPubMed
34.Dinev, D, Jordan, BW, Neufeld, B, et al.Extracellular signal regulated kinase 5 (ERK5) is required for the differentiation of muscle cells. EMBO Rep. 2001;2:829–34.CrossRefGoogle ScholarPubMed
35.English, JM, Pearson, G, Hockenberry, T, Shivakumar, L, White, MA, Cobb, MH.Contribution of the ERK5/MEK5 pathway to Ras/Raf signaling and growth control. J Biol Chem. 1999;274: 31588–92.Google Scholar
36.Cavanaugh, JE.Role of extracellular signal regulated kinase 5 in neuronal survival. Eur J Biochem. 2004;271:2056–9.CrossRefGoogle ScholarPubMed
37.Liu, L, Cavanaugh, JE, Wang, Y, Sakagami, H, Mao, Z, Xia, Z.ERK5 activation of MEF2-mediated gene expression plays a critical role in BDNF-promoted survival of developing but not mature cortical neurons. Proc Natl Acad Sci USA. 2003;100:8532–7.CrossRefGoogle Scholar
38.Sharma, G, Goalstone, ML.Dominant negative FTase (DNFTalpha) inhibits ERK5, MEF2C and CREB activation in adipogenesis. Mol Cell Endocrinol. 2005;245:93–104.CrossRefGoogle ScholarPubMed
39.Steen, E, Terry, BM, Rivera, EJ, et al.Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease-is this type 3 diabetes? J Alzheimers Dis. 2005;7:63–80.Google Scholar
40.Taubes, G.Neuroscience. Insulin insults may spur Alzheimer’s disease. Science. 2003;301:40–1.CrossRefGoogle ScholarPubMed
41.Hassing, LB, Johansson, B, Nilsson, SE, et al.Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer’s disease: a population-based study of the oldest old. Int Psychogeriatr. 2002;14:239–48.CrossRefGoogle Scholar